Lyophilisation & Freeze Drying USA on 29-30 April 2015, Iselin, New Jersey

There’s a growing demand for lyophilised pharmaceutical products that are contributing to an increase in the adoption of lyophilisation equipment and the need for lyophilised biopharmaceuticals and other formulations in the pharmaceutical industry. This is contributing to the projected rise in investment, currently dominated by North America, which is expected to reach $4.80 billion in 2020. This rate of growth is a result of new biologics and biosimilars, enhancing the need for lyophilisation equipment and services.

The requirements governed by the FDA and supported by ISPE focus on improving patient safety and product quality – supporting the adoption of lyophilisation in pharmaceutical manufacturing, with the necessity to lyophilise APIs and various formulations such as antibodies, antiviral drugs, insulin, biosimilars, injections and other therapeutic proteins.